Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
COMPASS Pathways plc (CMPS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights • Final NDA submission nearing completion and will be filed in the next two weeks • Launch readiness on track for expected launch in H12027, subject to FDA approval • Data from two positive Ph
How this was made
The 30-second read
Why it matters
The disclosed Phase 3 results and imminent NDA filing represent a pivotal milestone that could shift the company's valuation dramatically.
Market read
First‑hand disclosure of strong trial data and cash runway provides fresh material for traders; likely catalyst for price movement.
What to watch
Potential competition from other psychedelic programs and reimbursement uncertainty could limit upside.
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
Compass advanced its rolling NDA submission and reported a $444 million cash position expected to fund operations into 2028, but third-quarter selling, general and administrative expense rose to $33.0 million from $13.2 million as launch preparation accelerated and the company remained loss-making.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses - three months ended September 30GAAP | $23.46M | – | – |
| Selling, general and administrative expenses - three months ended September 30GAAP | $32.98M | – | – |
| Total operating expenses - three months ended September 30GAAP | $56.44M | – | – |
| Loss from operations - three months ended September 30GAAP | −$56.44M | – | – |
| Fair value change of warrant liabilities - three months ended September 30GAAP | $40.78M | – | – |
| Interest income - three months ended September 30GAAP | $3.60M | – | – |
| Benefit from R&D tax credit - three months ended September 30GAAP | $2.05M | – | – |
| Interest expense - three months ended September 30GAAP | −$1.50M | – | – |
| Foreign exchange gains (losses) - three months ended September 30GAAP | $ 23 | – | – |
| Other income - three months ended September 30GAAP | $ 556 | – | – |
| Total other income (expense), net - three months ended September 30GAAP | $45.5M | – | – |
| Loss before income taxes - three months ended September 30GAAP | −$10.94M | – | – |
| Income tax benefit (expense) - three months ended September 30GAAP | $1.11M | – | – |
| Net loss - three months ended September 30GAAP | −$9.83M | – | – |
| Net loss per share attributable to ordinary shareholders: basic - three months ended September 30GAAP | $ (0.07) | – | – |
| Net loss per share attributable to ordinary shareholders: diluted - three months ended September 30GAAP | $ (0.31) | – | – |
| Weighted average ordinary shares outstanding: basic - three months ended September 30GAAP | 138,719,375 | – | – |
| Weighted average ordinary shares outstanding: diluted - three months ended September 30GAAP | 162,568,025 | – | – |
| Comprehensive loss - three months ended September 30GAAP | −$10.01M | – | – |
| Research and development expenses - nine months ended September 30GAAP | $79.11M | – | – |
| Selling, general and administrative expenses - nine months ended September 30GAAP | $72.6M | – | – |
| Total operating expenses - nine months ended September 30GAAP | $151.7M | – | – |
| Loss from operations - nine months ended September 30GAAP | −$151.7M | – | – |
| Fair value change of warrant liabilities - nine months ended September 30GAAP | −$33.88M | – | – |
| Interest income - nine months ended September 30GAAP | $9.76M | – | – |
| Benefit from R&D tax credit - nine months ended September 30GAAP | $7.11M | – | – |
| Interest expense - nine months ended September 30GAAP | −$4.45M | – | – |
| Foreign exchange gains (losses) - nine months ended September 30GAAP | −$1.62M | – | – |
| Other income - nine months ended September 30GAAP | $1.59M | – | – |
| Total other income (expense), net - nine months ended September 30GAAP | −$21.50M | – | – |
| Loss before income taxes - nine months ended September 30GAAP | −$173.2M | – | – |
| Income tax benefit (expense) - nine months ended September 30GAAP | $ 786 | – | – |
| Net loss - nine months ended September 30GAAP | −$172.4M | – | – |
| Net loss per share attributable to ordinary shareholders: basic - nine months ended September 30GAAP | $ (1.35) | – | – |
| Net loss per share attributable to ordinary shareholders: diluted - nine months ended September 30GAAP | $ (1.35) | – | – |
| Weighted average ordinary shares outstanding: basic - nine months ended September 30GAAP | 128,084,630 | – | – |
| Weighted average ordinary shares outstanding: diluted - nine months ended September 30GAAP | 128,084,630 | – | – |
| Comprehensive loss - nine months ended September 30GAAP | −$172.6M | – | – |
Into 2028 outlook
- NoteThe current cash position is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2028.
- NoteFinal NDA submission will be filed in the next two weeks.
- NoteLaunch readiness on track for expected launch in H12027, subject to FDA approval.
What drove it
- Lower development expenses following completion of the Phase 3 program for COMP360 psilocybin treatment in TRD.
- Reduced discovery program expenses following termination of certain programs in connection with the fourth-quarter 2024 reorganization and related contract terminations in 2025.
- Increased facilities and other expenses, primarily from external consulting fees and contractors.
- Commercial-preparedness spending, including commercial infrastructure, market access and reimbursement capabilities, supply chain readiness and other launch preparation activities.
- Third-quarter net loss was affected by a $40.8 million gain from the fair value change of warrant liabilities.
Concerns
- The fair value of warrant liabilities fluctuates with the share price and can result in significant variability in reported net income or net loss.
- FDA approval, review timing, rescheduling, coverage and reimbursement remain conditions to the expected launch.
- The company stated that the rolling review process and/or the Commissioner's National Priority Voucher pilot program may not lead to a faster FDA review or approval process.
- The late-stage PTSD trial remains ongoing.
What to watch
- Final NDA submission expected in the next two weeks.
- Potential FDA review, approval and rescheduling following the NDA submission.
- Expected launch in H12027, subject to FDA approval.
- Part B data from the COMP006 Phase 3 trial for TRD.
- Progress of the registration-enabling late-stage PTSD trial.
- Commercial readiness across provider training, patient access, reimbursement, federal and state engagement, and support programs.
Balance sheet and cash flow
- Cash and cash equivalents were $444.0 million as of September 30, 2026, compared with $149.6 million as of December 31, 2025.
- Debt was $51.0 million as of September 30, 2026, compared with $31.6 million as of December 31, 2025.
- Restricted cash: $ 425 at September 30, 2026; $ 379 at December 31, 2025.
- Prepaid expenses and other current assets: $ 43,144 at September 30, 2026; $ 41,503 at December 31, 2025.
- Total current assets: $ 487,548 at September 30, 2026; $ 191,490 at December 31, 2025.
- Operating lease right-of-use assets: $ 3,454 at September 30, 2026; $ 3,424 at December 31, 2025.
- Deferred tax assets: $ 5,114 at September 30, 2026; $ 3,751 at December 31, 2025.
- Long-term prepaid expenses and other assets: $ 22,980 at September 30, 2026; $ 11,684 at December 31, 2025.
- Total assets: $ 519,096 at September 30, 2026; $ 210,349 at December 31, 2025.
- Accounts payable: $ 8,988 at September 30, 2026; $ 15,222 at December 31, 2025.
- Accrued expenses and other liabilities: $ 16,970 at September 30, 2026; $ 9,214 at December 31, 2025.
- Debt, current portion: $ 1,425 at September 30, 2026; $ 17,523 at December 31, 2025.
- Operating lease liabilities - current: $ 1,803 at September 30, 2026; $ 2,110 at December 31, 2025.
- Warrant liabilities: $ 296,677 at September 30, 2026; $ 203,726 at December 31, 2025.
- Total current liabilities: $ 325,863 at September 30, 2026; $ 247,795 at December 31, 2025.
- Debt, non-current portion: $ 49,561 at September 30, 2026; $ 14,110 at December 31, 2025.
- Operating lease liabilities - non-current: $ 1,605 at September 30, 2026; $ 1,292 at December 31, 2025.
- Total liabilities: $ 377,029 at September 30, 2026; $ 263,197 at December 31, 2025.
- Total shareholders' equity/(deficit): $ 142,067 at September 30, 2026; $ (52,848) at December 31, 2025.
Analysis
Compass remains a pre-commercial company focused on bringing COMP360 psilocybin treatment to the TRD market. The central operating development in the third quarter was that its rolling NDA submission was nearing completion, with the final submission expected in the next two weeks. Management said launch readiness remains on track for an expected H12027 launch, subject to FDA approval. The company also cited 52-week open-label COMP005 data and 6-month COMP006 data as reinforcing rapid onset, sustained durability and reproducibility of effect, while its late-stage PTSD trial remained underway.
Operating expenses were $ 56,437 for the three months ended September 30, 2026, compared with $ 40,536 in the prior-year period. Research and development expense declined to $ 23,458 from $ 27,325, reflecting lower clinical-trial costs following completion of the Phase 3 TRD program and lower discovery-program costs. Selling, general and administrative expense increased to $ 32,979 from $ 13,211, driven by commercial infrastructure, market access and reimbursement capabilities, supply chain readiness, and other launch preparation activities.
The reported third-quarter net loss was $ (9,831), compared with $ (137,717) a year earlier, but the release identifies warrant accounting as the primary driver of the improvement. Fair value change of warrant liabilities was a $ 40,782 gain in the 2026 quarter versus a $ (101,318) loss in the 2025 quarter. Loss from operations was $ (56,437), compared with $ (40,536), placing attention on the underlying increase in total operating expenses despite the materially smaller reported net loss.
Liquidity was $444.0 million of cash and cash equivalents as of September 30, 2026, compared with $149.6 million as of December 31, 2025. Debt was $51.0 million at September 30, 2026, compared with $31.6 million at December 31, 2025. Management guided that its current cash position is expected to fund operating expenses and capital expenditure requirements into 2028, framing the balance sheet around the NDA process, potential approval and launch preparation.
The near-term read centers on regulatory execution and commercialization readiness rather than revenue or margin delivery, neither of which was reported. The filing highlights the potential for a 1-2 month review period tied to the National Priority Voucher, but also explicitly states that the voucher and rolling review may not lead to a faster FDA review or approval process. The company is investing ahead of a potential launch while advancing the PTSD program, leaving regulatory outcomes, rescheduling, coverage and reimbursement as the principal stated execution dependencies.
Management, verbatim
Compass is leading one of the most important advances in mental health care in decades. Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we believe COMP360 has the potential to change the paradigm.
Kabir Nath, Chief Executive Officer of Compass Pathways
With the imminent completion of our NDA submission and the potential for a quick approval, we are executing with urgency and discipline to launch this much needed treatment in the first half of 2027.
Kabir Nath, Chief Executive Officer of Compass Pathways
At the same time, we continue to advance our PTSD program, extending the potential impact of COMP360 to additional patient populations with significant unmet need.
Kabir Nath, Chief Executive Officer of Compass Pathways
Not in the filing
stated, not guessed- Revenue was not reported.
- Revenue segments were not reported.
- Gross profit and gross margin were not reported.
- Non-GAAP measures were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Capital expenditures were not reported.
- Share repurchases and dividends were not reported.
- A tax rate was not reported.
- Prior-quarter comparisons were not reported.
- Prior-period outlook was not provided.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Compass Pathways (CMPS) is a Nasdaq‑listed biotech focused on psilocybin‑based treatments for treatment‑resistant depression (TRD).
Ticker impact
SEC 8‑K reports Q3 2026 results, positive Phase 3 data for COMP360 and a strong cash position of $444 M.
upward pressure as market prices in potential blockbuster launch and robust cash balance
Clinical data is material for a biotech; cash runway reduces financing risk, both are fresh disclosures.
Market effects
May boost sentiment in the psychedelic‑therapy and broader mental‑health biotech sector.
Limited to U.S. biotech investors; no broader regional effect.
Modest, confined to niche therapeutic area.
Counterpoint
If FDA delays or requires additional data, the hype could reverse, leading to a sell‑off.
Key entities
- companyCompass Pathways plc
Biotech developing COMP360 for TRD.
- executiveKabir Nath
CEO of Compass Pathways, provided commentary on trial data.
